Possible impact COVID-19 on the transport of medical radioisotopes
• Luxembourg, 01.04.2020
In this capacity, ESA has been in contact with the other co-chair – industry association of nuclear medicine - Nuclear Medicine Europe (NMEu), who expressed their concerns related to the impact of COVID-19 on the supply chain and in consequence on the availability of the most vital medical radioisotopes used in the nuclear medicine (namely Mo-99/Tc-99m).
Communication : Emergency Response Team (ERT)
• Brussels, 24 March 2020
The Security of Supply Working Group (SoS WG) Emergency Response Team (ERT) held a teleconference on 23 March 2020 to discuss the continuing impact of the COVID-19 epidemic on Mo-99 and other isotope production. Despite increasing challenges, the Mo-99 supply chain has not yet experienced any significant disruptions, though all levels of the supply chain remain vigilant and continue to adopt business continuity measures to provide a reliable supply.
Crossing the Covid-19 period
• Brussels, 24 March 2020
In these turbulent times, we are aware of the safety measures to be taken at all levels in conformity to the recommendations of national and international public health authorities. We are particularly careful not to endanger the health and safety of our members and their representatives within NMEu.
AIPES and the Transport Expert Working Group on Channel 4 TV
Channel 4’s TV host Victoria Macdonald and her crew came last week to interview the members of the Transport Experts Working Group about the possible consequences of the Brexit on the transport of radiopharmaceuticals to the UK.
Full segment of the broadcast can be seen here :
Cessation of Mo-99 Production Activities by NTP Radioisotopes Ltd.
• Brussels, 21 January 2019
ANSTO Press Release – OPAL reactor – Update
The AIPES Security of Supply working Group (SoS WG) composed of Mo-99 processors, research reactors, and generator manufacturers received an update from NTP Radioisotopes (South Africa) on 19 January concerning its Mo-99 and I-131 production activities.
NTP recently was authorized by the National Nuclear Regulator of South Africa to continue to perform routine Mo-99 production runs at around 40% of its capacity through the end of February 2019, which is the same level that has occurred since NTP returned to production in late November 2018. No Mo-99 or I-131 shortages have been experienced since NTP returned to service and none are anticipated in this upcoming period. NTP will update AIPES in late February regarding its Mo-99 and I-131 production activities.
Cessation of Mo-99 Production Activities by NTP Radioisotopes Ltd. (NTP)
• Brussels, 9 July 2018
ANSTO Press Release – OPAL reactor - Update
The AIPES Emergency Response Team (ERT*) composed of Mo-99 processors, research reactors, and generator manufacturers had a telecon on Monday 9 July 2018 to receive an update from NTP Radioisotopes (South Africa) on the temporary interruption of its Mo-99 and I-131 production activities. NTP reported that following meetings and information and documentation submissions to National Nuclear Regulator (NNR), it continues to await NNR’s feedback and approval in response to its request to resume Mo-99 production operations.
Processors and Generators expressed that for the time being, there is no major problems in the production initially planned, and that all are trying to manage through the NTP production outage. Situation will have to be reconsidered in the coming days/weeks if there are no changes.
The ERT also discussed the article issued...